RESULTS: The final analysis included 95 patients. Among these patients, 67 (70.53%) exhibited residual tumor, whereas 28 (29.47%) did not (pT0). Pathology findings showed that 44 (65.67%), 16 (23.88%), and 7 patients (10.45%) exhibited Gleason scores of G6, G7, and !G8, respectively. Fifty-seven and 10 patients exhibited pathologic T stages T2 and T3, respectively. Mean follow-up duration was 70.26 (AE34.67) months. Biochemical recurrence was observed in 11 patients; none were pT0 patients. Multivariate logistic regression showed that low prostate-specific antigen density after benign prostatic hyperplasia surgery and invisible lesion on multiparametric magnetic resonance imaging were significantly associated with pT0. Additionally, a combination of these factors showed an increase in the diagnostic accuracy of pT0, compared with mpMRI alone (AUC 0.805, 0.767, respectively); this combination showed sensitivity, specificity, and positive predictive values of 71.6%, 89.3%, and 94.1%, respectively. CONCLUSIONS: Our results suggest that patients with incidental prostate cancer who have both prostate-specific antigen density 0.08 after benign prostatic hyperplasia surgery as well as invisible cancer lesion on multiparametric magnetic resonance imaging should be considered for active surveillance.
INTRODUCTION AND OBJECTIVES:
The Clavien-Dindo classification is adopted to report complications in prostate cancer (PCa) patients undergoing robot-assisted radical prostatectomy (RARP). However, since it was not specifically developed for men undergoing RARP, this system might not be accurate in assessing the burden of procedure-specific complications.
METHODS: Overall, 446 PCa patients who received RARP AE pelvic lymph node dissection (PLND) between 2016 and 2018 were identified. Physicians prospectively collected perioperative data with a patient interview at 30-and 90-day. Data on complications classified according to the Clavien-Dindo system, LoS and readmission were collected. The discrimination of the Clavien-Dindo system in predicting a LoS above the median (pLoS) and/or readmission was assessed using the ROC-derived area under the curve (AUC). The most frequent complications associated with pLOS and/or readmission were identified and included in a novel risk score, where they conferred a score of 2 if one of them was present and 3 when !2 of them occurred. Any other complications conferred a score of 1. The model was internally validated and its accuracy was assessed using the ROC-derived AUC.
RESULTS: Median age was 65 years. Overall, 316 (70.9%) patients underwent a PLND. Median LoS was 3 days. A total of 159 (35.7%), 67 (15%), 102 (22.9%) and 109 (24.4%) men experienced overall, pre-and post-discharge complications with 44 (9.9%), 84 (18.8%) and 43 (9.4%) patients with Clavien-Dindo 1, 2 and !3 complications. The AUC of the Clavien-Dindo for predicting pLoS and post-discharge complications was 59%. Anastomotic leakage (n[35, 7.8%), urinary tract infections with fever (n[33, 7.4%) and lymphocele (n[22; 4.9%) were the most frequent complications associated with pLoS or readmission and were included in the risk score. The rate of pLOS and/or readmission was 25%, 75% and 90% among those with a risk score of 1 (other complications), 2 (the presence of one of the selected complications) and 3 (the combination of two or more of the selected complications). This risk score had an AUC of 82% when predicting pLoS and/or readmission.
CONCLUSIONS: We developed and internally validated a novel procedure-specific risk score to classify complications after RARP. Its use would facilitate reporting and grading postoperative outcomes in PCa patients undergoing RARP with a substantially higher accuracy when predicting prolonged LoS and/or readmission as compared to the Clavien-Dindo system.
